180 related articles for article (PubMed ID: 31841591)
1. Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
Arnold A; Yuan M; Price A; Harris L; Eberhart CG; Raabe EH
Neuro Oncol; 2020 Apr; 22(4):563-574. PubMed ID: 31841591
[TBL] [Abstract][Full Text] [Related]
2. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF
Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH
Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.
Poore B; Yuan M; Arnold A; Price A; Alt J; Rubens JA; Slusher BS; Eberhart CG; Raabe EH
Neuro Oncol; 2019 Feb; 21(2):252-263. PubMed ID: 30239952
[TBL] [Abstract][Full Text] [Related]
4. Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.
Li F; Bondra KM; Ghilu S; Studebaker A; Liu Q; Michalek JE; Kogiso M; Li XN; Kalapurakal JA; James CD; Burma S; Kurmasheva RT; Houghton PJ
Clin Cancer Res; 2022 Sep; 28(17):3836-3849. PubMed ID: 35797217
[TBL] [Abstract][Full Text] [Related]
5. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH
Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
7. Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target.
Hütt-Cabezas M; Karajannis MA; Zagzag D; Shah S; Horkayne-Szakaly I; Rushing EJ; Cameron JD; Jain D; Eberhart CG; Raabe EH; Rodriguez FJ
Neuro Oncol; 2013 Dec; 15(12):1604-14. PubMed ID: 24203892
[TBL] [Abstract][Full Text] [Related]
8. The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.
Rubens JA; Wang SZ; Price A; Weingart MF; Allen SJ; Orr BA; Eberhart CG; Raabe EH
Neuro Oncol; 2017 Oct; 19(10):1361-1371. PubMed ID: 28582547
[TBL] [Abstract][Full Text] [Related]
9. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.
Sigaud R; Rösch L; Gatzweiler C; Benzel J; von Soosten L; Peterziel H; Selt F; Najafi S; Ayhan S; Gerloff XF; Hofmann N; Büdenbender I; Schmitt L; Foerster KI; Burhenne J; Haefeli WE; Korshunov A; Sahm F; van Tilburg CM; Jones DTW; Pfister SM; Knoerzer D; Kreider BL; Sauter M; Pajtler KW; Zuckermann M; Oehme I; Witt O; Milde T
Neuro Oncol; 2023 Mar; 25(3):566-579. PubMed ID: 35882450
[TBL] [Abstract][Full Text] [Related]
10. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
[TBL] [Abstract][Full Text] [Related]
11. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK
Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
Wei BR; Hoover SB; Peer CJ; Dwyer JE; Adissu HA; Shankarappa P; Yang H; Lee M; Peat TJ; Figg WD; Simpson RM
Mol Cancer Ther; 2020 Nov; 19(11):2308-2318. PubMed ID: 32943547
[TBL] [Abstract][Full Text] [Related]
13. Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma.
Leclair NK; Lambert W; Roche K; Gillan E; Gell JJ; Lau CC; Wrubel G; Knopf J; Amin S; Anderson M; Martin JE; Bookland MJ; Hersh DS
Neurosurg Focus; 2022 Dec; 53(6):E15. PubMed ID: 36455272
[TBL] [Abstract][Full Text] [Related]
14. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
[TBL] [Abstract][Full Text] [Related]
15. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
[TBL] [Abstract][Full Text] [Related]
16. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
[TBL] [Abstract][Full Text] [Related]
17. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
[TBL] [Abstract][Full Text] [Related]
18. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
20. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
Nakabayashi H; Shimizu K
Cancer Sci; 2011 Feb; 102(2):393-9. PubMed ID: 21166955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
